Insights
Search Results
Client Highlights
5.27.26
Wilson Sonsini Advises Thea Energy on $100 Million Series B
On May 27, 2026, Thea Energy, a technology company advancing the stellarator for the commercialization of an abundant source of baseload fusion power, announced it has raised $100 million in Series B funding that draws support from Thomas Tull’s US Innovative Technology Fund (USIT), General Innovation Capital Partners (GICP), Linse Capital, Calm Ventures, Climate Capital, Divergent Capital, Emerald Technology Ventures, Gaingels, Idemitsu Kosan, Overlay Capital, Timescale Ventures, and Whatif Ventures. Wilson Sonsini Goodrich & Rosati advised Thea Energy on the transaction.
Client Highlights
5.20.26
Wilson Sonsini Advises Armada on $230 Million Series B
On May 19, 2026, Armada, the world’s first full-stack edge computing platform, revolutionizing connectivity, compute, and AI solutions where they’re needed most, announced that it has raised $230 million in an oversubscribed Series B financing at a $2 billion valuation. The round, which brings the company’s total funding to nearly half a billion dollars, was co-led by Overmatch, BlackRock, and 8090 Industries. Wilson Sonsini Goodrich & Rosati advised Armada on the transaction.
New strategic investors BlackRock, Johnson Controls, NightDragon, Mitsui, and Singtel Innov8 participated in the Series B round alongside existing investors including Overmatch, 8090 Industries, Felicis, Marlinspike, Shield Capital, Lux Capital, Founders Fund, Silent Ventures, Veriten, and Gladebrook. Armada will use the proceeds from the Series B to accelerate deployment of the U.S. AI stack and support customer demand growth across industries.
The Wilson Sonsini team that advised Armada on the transaction included Rezwan Pavri, Colin Conklin, Richa Sharma, Isaac Reed, and Jiyoon Song.
For more information, please see Armada’s news release.
New strategic investors BlackRock, Johnson Controls, NightDragon, Mitsui, and Singtel Innov8 participated in the Series B round alongside existing investors including Overmatch, 8090 Industries, Felicis, Marlinspike, Shield Capital, Lux Capital, Founders Fund, Silent Ventures, Veriten, and Gladebrook. Armada will use the proceeds from the Series B to accelerate deployment of the U.S. AI stack and support customer demand growth across industries.
The Wilson Sonsini team that advised Armada on the transaction included Rezwan Pavri, Colin Conklin, Richa Sharma, Isaac Reed, and Jiyoon Song.
For more information, please see Armada’s news release.
Client Highlights
5.19.26
Firm Advises Viktor on $75 Million Series A
On May 19, 2026, Viktor, a start-up building agentic AI coworkers, announced it has raised a $75 million Series A led by London-based venture capital firm Accel with participation from Bek Ventures, Kaya VC, Inovo VC, and Tenacity Capital. Angel investors, including Slack co-founders Stewart Butterfield and Cal Henderson, Synthesia CEO Victor Riparbelli, and executives from Google DeepMind, Figma, and ElevenLabs also participated in the funding round. Wilson Sonsini Goodrich & Rosati advised Viktor on the transaction.
Client Highlights
5.18.26
Wilson Sonsini Advises Calibre on $3.3 Million Pre-Seed Financing
On May 18, 2026, Calibre, a London-based start-up building AI for the testing, inspection, and certification (TIC) industry, announced it has raised $3.3 million in pre-seed funding. The round was led by Vicus Ventures and CIV, with participation from I2BF, 9 Yards Capital, Jigeum, and angel investors including Nikesh Arora. Wilson Sonsini Goodrich & Rosati advised Calibre on the transaction.
Client Highlights
5.18.26
Wilson Sonsini Advises Happl on $11 Million Series A
On May 11, 2026, Happl, a global benefits operating system for multinational employers, announced their $11 million Series A, led by Portage Ventures. The round included participation from F Capital and continued support from Y Combinator, 6 Degrees Capital, Haatch, and Ventures Together. Wilson Sonsini Goodrich & Rosati advised Happl on the transaction.
Client Highlights
5.13.26
Wilson Sonsini Advises Recursive on $650 Million Series A Funding at a $4.65 Billion Valuation
On May 13, 2026, Recursive, an AI start-up dedicated to advancing AI intelligence through recursive self-improvement, came out of stealth and announced that it raised over $650 million in its Series A round at a $4.65 billion valuation. The funding round was led by Google Ventures and Greycroft, with participation from chip makers AMD Ventures and NVIDIA. Wilson Sonsini Goodrich & Rosati advised Recursive on the transaction.
Client Highlights
5.07.26
Wilson Sonsini Advises Astranis on $450 Million Fundraise
On May 6, 2026, Astranis, an advanced satellite manufacturer, announced it has raised $450 million in new capital, bringing the company’s total raised to more than $1.2 billion as it scales to meet increased demand for its spacecraft designed for geostationary orbit and other high orbits. The funding includes a new $300 million Series E round co-led by Snowpoint Ventures and Franklin Templeton, with participation from Andreessen Horowitz, funds and accounts managed by affiliates of BlackRock, Baillie Gifford, and Fidelity Management & Research Company, as well as BAM Elevate, Nimble Partners, and Friends & Family Capital, along with other existing and new investors. A delayed-draw credit facility by Trinity Capital adds up to $155 million of additional capital to support the addition of new manufacturing capacity and support future growth. Wilson Sonsini Goodrich & Rosati advised Astranis on the transactions.
Client Highlights
5.06.26
Wilson Sonsini Advises BioOrbit on $13.2 Million Seed Round
On April 30, 2026, BioOrbit, a space manufacturing company developing hardware for the large-scale crystallization of protein drugs, announced the completion of a $13.2 million (£9.8 million) seed round co-led by LocalGlobe and BREEGA, with support from Seedcamp, Auxxo Female Catalyst Fund, Type One Ventures, 7percent Ventures and other investors. Wilson Sonsini Goodrich & Rosati advised BioOrbit on the transaction.
Client Highlights
5.06.26
Wilson Sonsini Advises Evantic Capital on Ethos’ $22.75 Million Series A
On May 6, 2026, Ethos, a London-based AI recruitment platform, announced a $22.75 million Series A round led by a16z with participation from General Catalyst, XTX Markets, Evantic Capital, and Common Magic. Wilson Sonsini Goodrich & Rosati advised Evantic Capital on the transaction.
Client Highlights
5.06.26
Wilson Sonsini Advises QuantWare on $178 Million Series B
On May 5, 2026, QuantWare, a leading industrial quantum processor company, announced a $178 million Series B equity fundraising following the announcement of VIO-40K™, a quantum processor architecture for 10,000 qubits, 100x larger than the state of the art today. New investors joining the round include Intel Capital, IQT, and ETF Partners, with participating existing investors including FORWARD.one and Invest-NL Deep Tech Fund, InnovationQuarter Capital, Ground State Ventures, and Graduate Ventures. The round was heavily oversubscribed and is the largest private round raised by a dedicated quantum processor company to date. Wilson Sonsini Goodrich & Rosati advised QuantWare on the transaction.
QuantWare is the only company that designs, fabricates, and integrates modular quantum processors on an open architecture at an industrial scale. The company is building KiloFab, the world’s largest dedicated quantum open architecture fab, increasing its production capacity by 20x to meet strong global customer demand.
The Wilson Sonsini team that advised QuantWare on the financing included:
Corporate
Daniel Glazer
Michael Labriola
Ashmi Bhagani
Elisa Sielski
Michael Soud
Daniel Jordan
Henry Oates
QuantWare is the only company that designs, fabricates, and integrates modular quantum processors on an open architecture at an industrial scale. The company is building KiloFab, the world’s largest dedicated quantum open architecture fab, increasing its production capacity by 20x to meet strong global customer demand.
The Wilson Sonsini team that advised QuantWare on the financing included:
Corporate
Daniel Glazer
Michael Labriola
Ashmi Bhagani
Elisa Sielski
Michael Soud
Daniel Jordan
Henry Oates
Client Highlights
5.05.26
Wilson Sonsini Advises Off Piste Capital on Launch of Fund
On April 29, 2026, Off Piste Capital, a venture capital firm launched to support exceptional founders building the future, announced its first close of Off Piste Fund I with a group of strategic limited partners, including Edition Ventures. The fund is designed to invest in companies building the systems and infrastructure of the future. Wilson Sonsini Goodrich & Rosati advised Off Piste on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Represents Investors in Windward Bio’s $165 Million Crossover Financing
On May 4, 2026, Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. Wilson Sonsini Goodrich & Rosati represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in the transaction.
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included: